Chronic Kidney Disease-induced Muscle Atrophy: Molecular Mechanisms and Promising Therapies

Kexin Wang,Qingyuan Liu,Mingyu Tang,Guangdong Qi,Chong Qiu,Yan Huang,Weiran Yu,Wei Wang,Hualin Sun,Xuejun Ni,Yuntian Shen,Xingxing Fang
DOI: https://doi.org/10.1016/j.bcp.2022.115407
IF: 6.1
2023-01-02
Biochemical Pharmacology
Abstract:Chronic kidney disease (CKD) is a high-risk chronic catabolic disease due to its high morbidity and mortality. CKD is accompanied by many complications, leading to a poor quality of life, and serious complications may even threaten the life of CKD patients. Muscle atrophy is a common complication of CKD. Muscle atrophy and sarcopenia in CKD patients have complex pathways that are related to multiple mechanisms and related factors. This review not only discusses the mechanisms by which inflammation, oxidative stress, mitochondrial dysfunction promote CKD-induced muscle atrophy but also explores other CKD-related complications, such as metabolic acidosis, vitamin D deficiency, anorexia, and excess angiotensin II, as well as other related factors that play a role in CKD muscle atrophy, such as insulin resistance, hormones, hemodialysis, uremic toxins, intestinal flora imbalance, and miRNA. We highlight potential treatments and drugs that can effectively treat CKD-induced muscle atrophy in terms of complication treatment, nutritional supplementation, physical exercise, and drug intervention, thereby helping to improve the prognosis and quality of life of CKD patients.
pharmacology & pharmacy
What problem does this paper attempt to address?